Press release
United States HER2+ Gastric Cancer Market Forecast 2024-2031: Rising Incidence, Research Investments, and Breakthrough Approvals Shaping Oncology Treatment Strategies | Astrazeneca, Genentech USA, Bristol-Myers Squibb
Global HER2+ Gastric Cancer Market reached with a CAGR during the forecast period 2024-2031.The HER2+ gastric cancer market focuses on therapies for patients with gastric cancer overexpressing the HER2 protein. Targeted therapies, such as trastuzumab, along with chemotherapy, are standard treatments. Market growth is supported by increasing incidence of gastric cancer in Asia and other regions. The pipeline includes novel monoclonal antibodies, antibody-drug conjugates, and immunotherapies. Rising adoption of biomarker testing enhances patient stratification and treatment outcomes. Continued research and global approvals are driving progress in this specialized oncology segment.
π Download Sample Report to Identify Emerging Deals & Opportunities in the HER2+ Gastric Cancer Market Landscape:- https://datamintelligence.com/download-sample/her2-gastric-cancer-market?rk
β HER2+ Gastric Cancer Market Recent Developments 2025:
United States: Recent Industry Developments
β In August 2025, Roche expanded its HER2-targeted therapies portfolio for gastric cancer in the U.S., focusing on personalized treatment options.
β In July 2025, AstraZeneca launched next-generation HER2 inhibitors, supporting improved patient survival and treatment adherence.
β In June 2025, Pfizer partnered with oncology centers to implement HER2+ gastric cancer clinical protocols, integrating precision medicine approaches.
Europe: Recent Industry Developments
β In July 2025, Roche Europe introduced advanced HER2-targeted therapies, enhancing treatment outcomes for gastric cancer patients across EU hospitals.
β In June 2025, AstraZeneca Europe expanded its gastric cancer pipeline, integrating novel HER2 inhibitors and combination therapies.
β In May 2025, Amgen Europe partnered with clinics to deploy next-generation HER2+ treatment protocols, improving patient quality of life.
Japan: Recent Industry Developments
β In July 2025, Takeda Pharmaceutical launched HER2-targeted therapies for gastric cancer in Japan, supporting precision oncology initiatives.
β In June 2025, Chugai Pharmaceutical expanded its gastric cancer therapy portfolio, integrating HER2-targeted approaches.
β In May 2025, Astellas Pharma partnered with oncology centers to implement advanced treatment protocols, improving survival outcomes.
β HER2+ Gastric Cancer Market Trends:
HER2+ gastric cancer is a subtype of stomach cancer characterized by overexpression of the HER2 protein, making it responsive to targeted therapies. The market includes monoclonal antibodies, tyrosine kinase inhibitors, and combination therapies, aimed at improving survival rates and reducing tumor progression. Growth is driven by increasing gastric cancer incidence, early diagnostic improvements, and the adoption of personalized oncology treatments.
Advances in targeted therapies, antibody-drug conjugates (ADCs), and immunotherapy combinations are expanding treatment options. North America and Europe dominate due to advanced healthcare infrastructure and clinical trial activity, while Asia-Pacific is witnessing rapid growth, particularly in countries with high gastric cancer prevalence like Japan, China, and South Korea. Challenges include high therapy costs and limited access in emerging regions.
β HER2+ Gastric Cancer Market Competitve Landscape:
Astrazeneca, Genentech USA, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, Linton Pharm, Shanghai Henlius Biotech, Sanofi, Pfizer, Novartis AG and among others
Research Methodology
We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.
π Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/her2-gastric-cancer-market
β Segment Covered in the HER2+ Gastric Cancer Market:
By Therapy: Immunotherapy, Chemotherapy, Radiation Therapy, Targeted Therapy
By Stage: Stage I, Stage II, Stage III, Stage IV
By End User: Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Others
β This Report Includes:
β Comprehensive go-to-market strategies with actionable insights.
β Unbiased evaluation of overall market performance.
β Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.
β Tailored regional and country-level reports with detailed localized analysis available on request.
β Identification of niche segments and high-growth regions presenting strong opportunities.
β Accurate regional forecasts using both top-down and bottom-up approaches.
π Get Corporate Access to Live HER2+ Gastric Cancer Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=her2-gastric-cancer-market
β Regional Analysis for HER2+ Gastric Cancer Market:
β₯ North America (U.S., Canada, Mexico)
β₯ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
β₯ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
β₯ South America (Colombia, Brazil, Argentina, Rest of South America)
β₯ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
β Frequently asked questions:
β What is the global sales, production, consumption, import, and export value of the HER2+ Gastric Cancer Market?
β Who are the key global manufacturers, and what is their operational performance?
β What are the major opportunities and threats in the global HER2+ Gastric Cancer Market?
β Which product types or end-users show the most growth potential and market share?
β What challenges and constraints are impacting the HER2+ Gastric Cancer Market?
β What sales, marketing, and distribution channels are used globally?
π Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription
β Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
β Competitive Landscape
β Sustainability Impact Analysis
β KOL / Stakeholder Insights
β Unmet Needs & Positioning, Pricing & Market Access Snapshots
β Market Volatility & Emerging Risks Analysis
β Quarterly Industry Report Updated
β Live Market & Pricing Trends
β Import-Export Data Monitoring
β Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States HER2+ Gastric Cancer Market Forecast 2024-2031: Rising Incidence, Research Investments, and Breakthrough Approvals Shaping Oncology Treatment Strategies | Astrazeneca, Genentech USA, Bristol-Myers Squibb here
News-ID: 4205466 • Views: β¦
More Releases from DataM Intelligence 4market Research LLP
Graphite Electrode Market to Expand at 6.2% CAGR as EAF-Based Green Steel, UHP E β¦
The Global Graphite Electrode Market reached USD 8.1 billion in 2022 and is expected to reach USD 13.0 billion by 2031 growing with a CAGR of 6.2% during the forecast period 2024-2031. , according to DataM Intelligence.
United States: Recent Industry Developments
β
In October 2025, GrafTech International Ltd. expanded its U.S. ultra-high-power graphite electrode production by 20% at its Ohio facilities, partnering with major steelmakers such as Nucor to support electricβ¦
Aluminium Casting Market Set to Soar at 5.3% CAGR Through 2032 Driven by Automot β¦
The global aluminum casting market reached US$ 79.07 billion in 2023, rising to US$ 83.50 billion in 2024, and is expected to reach US$ 126.22 billion by 2032, growing at a CAGR of 5.3% from 2025 to 2032. according to DataM Intelligence.
United States: Recent Industry Developments
β
In October 2025, Alcoa Corporation expanded its U.S. high-pressure die casting capacity by 20% in Tennessee facilities, partnering with automotive OEMs like Ford toβ¦
Remote Infrastructure Management (RIM): Driving Operational Efficiency, Cybersec β¦
Remote Infrastructure Management (RIM) refers to the practice of managing and monitoring an organization's IT infrastructure such as servers, networks, storage systems, and endpoints remotely using specialized tools and technologies. This includes activities like system monitoring, performance optimization, security management, patching, troubleshooting, and backup management, all handled without requiring on-site presence.
Download Exclusive Sample: https://www.datamintelligence.com/download-sample/remote-infrastructure-management-market?rk
RIM helps organizations ensure business continuity, minimize downtime, and optimize operational efficiency. It is particularly valuable forβ¦
Surface Protection Films Market Growth: Self-Healing, Nanocoatings, and Smart Fi β¦
Surface Protection Films (SPFs) are thin, flexible polymeric films applied to surfaces to safeguard them from scratches, dust, dirt, UV exposure, and minor impacts during manufacturing, storage, transportation, or installation. These films are widely used in industries such as electronics, automotive, construction, aerospace, furniture, and metal fabrication to preserve the aesthetic and functional quality of surfaces.
Download Exclusive Sample: https://www.datamintelligence.com/download-sample/surface-protection-films-market?rk
SPFs are typically made from materials like polyethylene (PE), polypropylene (PP), polyurethaneβ¦
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio β¦
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+β¦
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T β¦
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growthβ¦
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sampleβ¦
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products inβ¦
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyzeβ¦
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drugβ¦
